Combination treatment of PARP inhibitor, BMN 673 and DNMT inhibitor, Azacytidine: A potential therapy for BRCA negative and positive, triple negative breast cancers

被引：0
|
作者：
Chowdhury, Khadiza [1 ]
Lapidus, Rena G. [1 ]
Choi, Eun Yong [1 ]
Baylin, Stephen [2 ]
Rassool, Feyruz V. [1 ]
机构：
[1] Univ Maryland, Baltimore, MD 21201 USA
[2] Johns Hopkins Univ, Baltimore, MD USA
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-2948
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2948
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Combining electrochemotherapy with PARP inhibitor olaparib in triple negative breast cancer in vitro and in vivo
    Bosnjak, M.
    Jesenko, T.
    Markelc, B.
    Janzic, L.
    Cemazar, M.
    Sersa, G.
    FEBS OPEN BIO, 2021, 11 : 430 - 431
  • [32] Antitumor effects of WEE1 inhibitor, AZD1775 alone or in combination with PARP inhibitor in triple negative breast cancer cells
    Ha, Dong Hyeon
    Min, Arrum
    Kim, Seongyeong
    Kim, So Hyeon
    Jang, Hyemin
    Kim, Yu Jin
    Jung, Daeun
    Park, YoonJung
    Suh, Koung Jin
    Lee, Kyung-Hun
    Kim, Tae-Yong Kiim
    Im, Seock-Ah
    CANCER RESEARCH, 2018, 78 (13)
  • [33] BMN673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
    Shen, Yuqiao
    Rehman, Farah L.
    Feng, Ying
    Boshuizen, Julia
    Bajrami, Ilirjana
    Elliott, Richard
    Wang, Bing
    Lord, Christopher J.
    Post, Leonard E.
    Ashworth, Alan
    CLINICAL CANCER RESEARCH, 2013, 19 (18) : 5003 - 5015
  • [34] Potential Combination Therapy for Triple-Negative Breast Cancer
    不详
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 (06) : 1279 - 1279
  • [35] Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer
    Eskiler, Gamze Guney
    Cecener, Gulsah
    Egeli, Unal
    Tunca, Berrin
    PHARMACEUTICAL RESEARCH, 2018, 35 (11)
  • [36] Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer
    Anita K. Mehta
    Emily M. Cheney
    Christina A. Hartl
    Constantia Pantelidou
    Madisson Oliwa
    Jessica A. Castrillon
    Jia-Ren Lin
    Katie E. Hurst
    Mateus de Oliveira Taveira
    Nathan T. Johnson
    William M. Oldham
    Marian Kalocsay
    Matthew J. Berberich
    Sarah A. Boswell
    Aditi Kothari
    Shawn Johnson
    Deborah A. Dillon
    Mikel Lipschitz
    Scott Rodig
    Sandro Santagata
    Judy E. Garber
    Nadine Tung
    José Yélamos
    Jessica E. Thaxton
    Elizabeth A. Mittendorf
    Peter K. Sorger
    Geoffrey I. Shapiro
    Jennifer L. Guerriero
    Nature Cancer, 2021, 2 : 66 - 82
  • [37] Preclinical activity of the poly (ADP-ribose) polymerase (PARP) inhibitor ABT-888 in combination with irinotecan in ovarian and triple negative breast cancers
    Nechiporchik, N.
    Lieb, K.
    Marquette, L.
    Polin, L.
    Peters, G. J.
    Chen, A.
    Ethier, S. P.
    LoRusso, P. M.
    Burger, A. M.
    EJC SUPPLEMENTS, 2010, 8 (07): : 64 - 64
  • [38] Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer
    Mehta, Anita K.
    Cheney, Emily M.
    Hartl, Christina A.
    Pantelidou, Constantia
    Oliwa, Madisson
    Castrillon, Jessica A.
    Lin, Jia-Ren
    Hurst, Katie E.
    de Oliveira Taveira, Mateus
    Johnson, Nathan T.
    Oldham, William M.
    Kalocsay, Marian
    Berberich, Matthew J.
    Boswell, Sarah A.
    Kothari, Aditi
    Johnson, Shawn
    Dillon, Deborah A.
    Lipschitz, Mikel
    Rodig, Scott
    Santagata, Sandro
    Garber, Judy E.
    Tung, Nadine
    Yelamos, Jose
    Thaxton, Jessica E.
    Mittendorf, Elizabeth A.
    Sorger, Peter K.
    Shapiro, Geoffrey I.
    Guerriero, Jennifer L.
    NATURE CANCER, 2021, 2 (01) : 66 - +
  • [39] Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer
    Gamze Guney Eskiler
    Gulsah Cecener
    Unal Egeli
    Berrin Tunca
    Pharmaceutical Research, 2018, 35
  • [40] Combination of the PARP inhibitor E7449 with eribulin plus /- carboplatin in preclinical models of triple negative breast cancer
    McGonigle, Sharon
    Wu, Jiayi
    Kolber-Simonds, Donna
    Twine, Natalie C.
    Shie, Jue-Lon
    Taylor, Noel
    Agoulnik, Sergei
    Dezso, Zoltan
    McGrath, Shannon
    Matijevic, Mark
    Xu, Shanqin
    Kuznetsov, Galina
    Woodall-Jappe, Mary
    Nomoto, Kenichi
    CANCER RESEARCH, 2015, 75
12345